Antibody opsonins from cystic fibrosis (CF) patients were investigated using nonmucoid and mucoid lipopolysaccharide (LPS) immunotype 1 Pseudomonas aeruginosa as bacterial ligands and PMN phagocytes. CF sera were compared to normal sera, polyvalent PA LPS hyperimmune globulin, and isotype switch variant monoclonal antibodies (MAbs) specific for type 1 PA LPS. Sera from PA-infected CF patients (CF PA+) had elevated levels of PA LPS and alginate IgG antibodies and promoted significantly greater antibody-dependent PMN chemiluminescence responses than sera from uninfected CF patients (CF PA-) or normal human sera (NHS). After adjustment for autologous IgG PA LPS antibody content, however, CF PA+ sera had less antibody-dependent opsonic activity than sera from CF PA-patients (P < 0.025) or NHS (P < 0.0025), suggesting qualitative opsonic defects of IgG PA LPS antibodies in CF PA+ sera. Antigen-specific immunoprecipitation of PA LPS antibodies enhanced opsonization by 40% of CF PA+ sera while uniformly reducing that from CF PAsera (P < 0.01), indicating LPS-specific nonopsonic antibodies in some CF PA+ sera. Alginate antibodies were not critical opsonins in most uninfected CF patient sera. PA LPS IgG antibodies isolated by immunoaffinity chromatography from NHS, hyperimmune globulin, and CF PA-sources were opsonic and had greater activity at equal antigen-binding concentration than identical antibodies isolated from infected CF patients (P < 0. Cystic fibrosis (CF)' is characteristically complicated by chronic Pseudomonas aeruginosa (PA) endobronchial infection with progressive lung destruction (1). While the basis for increased susceptibility of CF patients to chronic PA lung infection remains unknown, notable defects in systemic immunity have not been found; it is therefore thought to be due to impaired expression of host defense mechanisms in the lung, such as altered respiratory epithelial adherence characteristics or mucociliary clearance (2).
Introduction
Antibody opsonins from cystic fibrosis (CF) patients were investigated using nonmucoid and mucoid lipopolysaccharide (LPS) immunotype 1 Pseudomonas aeruginosa as bacterial ligands and PMN phagocytes. CF sera were compared to normal sera, polyvalent PA LPS hyperimmune globulin, and isotype switch variant monoclonal antibodies (MAbs) specific for type 1 PA LPS. Sera from PA-infected CF patients (CF PA+) had elevated levels of PA LPS and alginate IgG antibodies and promoted significantly greater antibody-dependent PMN chemiluminescence responses than sera from uninfected CF patients (CF PA-) or normal human sera (NHS). After adjustment for autologous IgG PA LPS antibody content, however, CF PA+ sera had less antibody-dependent opsonic activity than sera from CF PA-patients (P < 0.025) or NHS (P < 0.0025), suggesting qualitative opsonic defects of IgG PA LPS antibodies in CF PA+ sera. Antigen-specific immunoprecipitation of PA LPS antibodies enhanced opsonization by 40% of CF PA+ sera while uniformly reducing that from CF PAsera (P < 0.01), indicating LPS-specific nonopsonic antibodies in some CF PA+ sera. Alginate antibodies were not critical opsonins in most uninfected CF patient sera. PA LPS IgG antibodies isolated by immunoaffinity chromatography from NHS, hyperimmune globulin, and CF PA-sources were opsonic and had greater activity at equal antigen-binding concentration than identical antibodies isolated from infected CF patients (P < 0.01-0.05); the majority of isolates from CF PA+ sera did not promote PMN oxidative responses above nonopsonic baseline. A potential isotypic basis for these findings was supported by differences in PMN responses to PA opsonized with MAbs of identical specificity but differing isotypes. PA LPS-specific IgG antibodies inhibiting PMN oxidative responses in infected patient sera demonstrate antigen-specific immunomodulation of host responses by chronic bacterial parasitism in CF, which may play a role in the pathophysiology of lung disease.
Cystic fibrosis (CF)' is characteristically complicated by chronic Pseudomonas aeruginosa (PA) endobronchial infection with progressive lung destruction (1) . While the basis for increased susceptibility of CF patients to chronic PA lung infection remains unknown, notable defects in systemic immunity have not been found; it is therefore thought to be due to impaired expression of host defense mechanisms in the lung, such as altered respiratory epithelial adherence characteristics or mucociliary clearance (2) .
Once the CF respiratory epithelium is colonized, it is very likely that additional factors come into play to allow persistence of PA endobronchial infection despite a vigorous immune response. These factors apparently include both adaptive changes in bacterial phenotype and maladaptive developments in host defense. With regard to the latter, perhaps the most striking observation has been that opsonization of PA with serum from CF patients infected with PA (CF PA+) reduces resulting lung macrophage phagocytosis and killing in vitro when compared with serum from healthy individuals or CF patients free of PA infection [CF PA-] (3-5). Notably, this opsonic defect is antigen-specific, as opsonization of other microbes with CF PA+ serum is normal (4) (5) (6) . Defective opsonization has also been found using CF PA+ lipopolysaccharide (LPS)-specific IgG antibodies isolated from serum or bronchoalveolar lavage fluid, implicating these antibodies in the opsonic deficiency (7, 8) . The defect has been demonstrated using lung macrophages from human and several other mammalian species, but was not apparent in one study when human PMN or monocytes were employed as target phagocytes in a single time point uptake assay (9) . Discrepancies in phagocytosis of opsonized PA by different cell types may be due to heterogeneity in fine specificity and expression of IgG Fc receptors (FcyR) (10) . For example, lung macrophages display a more restricted FcyR repertoire than PMN or monocytes as determined by IgG 1-4 subclass binding and FcyRmediated effector assays ( 11).
PA LPS IgG antibodies are partly fragmented in CF airways by proteolytic enzymes, potentially contributing to local opsonic deficiency (8) . However, fragmentation is not found in corresponding serum antibodies, which are also dysfunctional (3-5, 7, 12) . The specificity of the opsonic defect suggests an antigen-driven Fcy-based alteration in antibody function, such as production of functionally nonopsonizing isotypes (12, 13) . This mechanism is also supported by induction of nonopsonizing serum antibodies in cats after parenteral hyperimmunization with PA LPS (14) . Moreover, striking shifts in levels and proportions of IgG1-4 immunoglobulins, and more specifically in IgGl-4 antibody responses to PA LPS, occur in CF PA+ patients (12, (15) (16) (17) (18) .
In studying the CF opsonic defect, we revisited the question of whether it could be detected using PMN as target phagocytes. We reasoned that induction of nonopsonizing antibodies in CF PA+ sera could be detected with PMN if the magnitude, antigenic specificity, and isotypic distribution of antibody responses were taken into account. We therefore compared the opsonic activity of CF PA+ sera to that of CF PA-sera, normal nonimmune sera, polyclonal PA LPS antibody-enriched hyperimmune globulin derived from immune normal donors (Ps-ivIG), and a set of isotype switch murine monoclonal antibodies specific for PA LPS. IgG and IgG subclass antibody levels were determined and related to opsonic activity. The functional activity of isolated LPS antibodies, and the effect of their removal from serum, were assessed. We found that along with high levels of PA LPS-specific IgG, IgG2 and IgG4 antibodies, PA LPS-specific IgG After equilibration in the luminometer counting chambers for at least 1 h at 370C, unstimulated PMNs were monitored for return ofCL to background emission levels (< 0.5 mV). Then, immediately after the addition of the bacterial suspension, light emission of each vial was recorded for 6 s and at subsequent 5-min intervals for 150 min. All determinations were performed in duplicate. Results were expressed as the mean value after automatic subtraction of background.
Bactericidal assay. PMN were isolated as described above, adjusted to a final concentration of 106 cfu/ml, and incubated with 107 cfu/ml PA in duplicate tubes at 370C for 5-90 min. Phagocytosis was stopped by addition ofcold PBS. PMN-associated PA were isolated by centrifugation at 160 g for 5 min at 4VC. Bactericidal activity was determined by digestion of PA-associated PMN pellets with 1 N NaOH or 1% Triton for 10 min under vigorous vortexing. Serial 10-fold dilutions of samples in PBS were prepared, and l-ml aliquots plated on MacConkey media plates. Colony forming units were counted after 1-2 d incubation at 370C.
PA LPS and alginate-specific IgG serum antibodies. Samples were tested for IgG antibodies to PA-l LPS using purified antigen isolated from the autologous ATCC strain 27312 (List Biological Laboratories, Campbell, CA). Serum PA-1 LPS IgG antibody content was measured by ELISA as previously described, with an internal intraplate high-titer standard serum whose ELISA unit values (EU) were calibrated by an anti-isotype standardization method, where 1 EU corresponds to 0.01 ,ug/ml (19) . Alginate antibodies were determined using commercial sodium alginate (Sigma Chemical Co., St Louis, MO) as the antigen (26-28).
Alginate 200 ,g/ml in carbonate buffer pH 9.6 was incubated in polyvinylchloride flat bottom microtiter plate wells (100 ,l/well) 1 h at 37°C. After aspiration, 1% normal goat serum (NGS) in PBS was added (200 ,l/well), incubated 1 h at 37°C, aspirated, and wells washed three times with PBS-0. 1% Tween. Serum samples diluted in NGS-PBS were added (100 Ml/well) for 2 h at 37°C, aspirated, and wells washed. Polyclonal goat antihuman IgG-peroxidase conjugate (Sigma Chemical Co.) 1:1,000 in NGS-PBS was then added, incubated 1 h at 37°C, aspirated, and wells washed. The reaction was developed with o-phenylene-diamine 0.5 mg/ml in citrate-phosphate buffer, pH 6.0, containing hydrogen peroxide (4 ,l 30% H202/l0 ml substrate buffer) for 15 and incubated in microfuge tubes in checkerboard fashion with an equal volume of each antigen discretely at three log concentrations (1 mg, 100 ,ug, and 1 ,ug/ml for alginate; 10 mg, 1 mg, and 100 qg/ml for PA LPS). After incubation for 3 h at 22°C
followed by overnight incubation at 4VC, the mixtures were then centrifuged at 3,000 rpm for 20 min. The supernatants were then tested in ELISA along with corresponding untreated samples. Percent inhibition by preincubation with autologous and heterologous antigen was calculated.
Postantigen absorption CL studies. To determine the effect of removal of PA LPS or alginate antibodies on PMN CL responses, serum samples were incubated with the respective antigens in a checkerboard fashion. Serial dilutions of sera were incubated with LPS and alginate essentially as described above for ELISA specificity studies. Sera diluted in HBSS-Ca2" were first decomplemented by heat inactivation at 560C for 30 min, followed by incubation with dilutions of antigen in identical buffer overnight at 4VC. For most samples, immunoadsorption was maximal at 1:20 serum dilution with 500 ,g/ml LPS concentration. Samples were then centrifuged at 2,500rpm for 90 min and the supernatant decanted for postadsorption assay. Specific immunoprecipation of autologous antibody was verified by ELISA. The sample for each individual demonstrating maximal immunoprecipitation was concentrated to initial volume by pervaporation and subsequently used to opsonize PA for simultaneous PMN CL assay along with the corresponding unadsorbed autologous serum sample.
Isolation of PA-I LPS antibodies from serum. PA-l specific IgG antibodies were isolated from serum essentially as described by Fick et al. (29) . PA-1 immunoadsorbent columns were prepared as follows: 6 g cyanogen bromide-activated Sepharose 4B (Pharmacia Fine Chemi- Serum IgG fractions were prepared by ammonium sulfate precipitation and ion exchange chromatography. Serum samples were mixed with half volumes (33%) of saturated (NH4)2SO4 solution for 2 h at room temperature. After centrifugation for 20 min at 13,000 g at 4°C, precipitates were dissolved in distilled water and dialyzed extensively against 0.01 M phosphate buffer, pH 8.0. After repeat centrifugation supernatants were used for DE-52 (diethylamino-ethylcellulose; Whatman, Inc., Clifton, NJ) ion-exchange column chromatography. Columns were equilibrated with 0.01 M phosphate buffer, pH 8.0. Approximately 3.5-ml vol of supernatant was applied to the DE-52 column and 5-min timed fractions were collected and assayed for protein at OD280 nm. Protein peaks were assayed for immunoglobulins by double immunodiffusion against antisera to human IgG, IgM, and IgA. The major, early IgG-containing portion of the first peak was dialyzed extensively in borate-saline buffer, pooled, assayed for protein at OD280, and used for the antibody isolation procedure.
Antibody isolations from IgG serum fractions were performed by pipetting off borate buffer from immunosorbent gels, leaving -10 ml gel volume. Then 5-10 ml (1-4 mg/ml) IgG fraction was added and gently mixed at room temperature for 20 min and passed through a sintered glass filter, followed by a second incubation and filtration. The gel was then extensively washed (150 ml) with borate buffer until the OD280 ofthe wash eluate was < 0.02. Antibodies were then eluted from the gel with 10 ml glycine HCl passing through the filter twice. The eluate was transferred into a tube with 1 ml 5% NH4HCO3 to keep the pH close to 7.0. The solution was then dialyzed with saline and concentrated down to 0.5-1 ml by centrifugation at 3,000 g using Centriprep 10 concentrators (Amicon Corp., Danvers, MA). The gel was regenerated by washing with 100 ml glycine buffer followed by three 50-ml washes with borate-saline buffer. The protein level of collected fractions was determined spectrophotometrically at OD280 and the PA-I antigen-binding activity by ELISA. For functional studies, PA-I antibody isolates were employed both at maximal concentration and again after dilution to equal antigen-binding titers as determined by ELISA. PA-I was opsonized with antibody isolates as described above.
PA LPS and alginate IgG subclass antibodies. Subclass-specific ELISA for IgG2 and IgG4 antibodies to PA-l LPS and alginate were performed as previously described (12, 13 
Results
Opsonization ofnonmucoid PA. The addition of unopsonized NMPA to temperature-equilibrated normal human PMN yielded low chemiluminescence responses (peak CL = 5.4±1.2 mV-s). PMN CL responses to opsonized NMPA, shown in Fig.  1 , significantly increased after opsonization with CF PA+ sera (mean peak CL = 26.3+2.9, P < 0.005) and, to a lesser degree, with CF PA-sera (mean peak CL = 11.7+1.7, P < 0.05). Induction of PMN oxidative activity by CF PA+ sera was not significantly different in kinetic pattern or peak responses than that obtained with Ps-ivIG. In contrast, PMN CL activity induced by PA opsonized with CF PA-sera was significantly lower than Ps-ivIG or CF PA+ sera and similar to that promoted by NHS (Fig. 1) > 2 at 30 min). Killing of MPA in the absence of complement was greatest after opsonization with the IgG2a or IgG2b MAbs, followed by the IgM MAb (log reductions of cfu/cm3 at 30 min = 1.90, 1.85, and 1.72, respectively; nonopsonic killing = 1.01 log reduction). Serum PA antibodies and opsonization. PA LPS and alginate IgG, IgG2, and IgG4 antibody responses were evaluated by enzyme-linked immunosorbent assays. Assay specificity was examined by cross-inhibition experiments in which various concentrations of each antigen were preincubated with heat-inactivated sera and resultant complexes removed by immunoprecipitation before ELISA (see Methods). Inhibition of antibody binding to immobilized PA LPS in a high-titer standard serum was dose-dependent and antigen-specific: at 10-2 serum dilution, LPS antibody binding was inhibited 40% by preincubation with 100 jig/ml LPS, 88% with 1 mg/ml, and 95% by 10 mg/ml, while no inhibition occurred after preincubation with alginate over a 4 log range (1 -1,000 ,ug/ml). Conversely, antibody binding to alginate was inhibited 66% by 1 Ag/ml alginate, 72% by 100 ,ug/ml, and 83% by 1 mg/ml, while LPS inhibited by only 9-19% at 0.1-10 mg/ml. Serum IgG, IgG2, and IgG4 PA LPS antibody levels in three study groups are shown in Table I . CF PA+ serum anti- The peak PMN CL response induced by opsonization of NMPA with heat-inactivated serum for each individual was divided by the autologous PA LPS IgG antibody concentration in order to derive a value for antibody-mediated opsonization at equivalent antigen-binding level. Fig. 5 displays the PMN CL-producing activity of CF PA+ sera, CF PA-sera, and NHS after this adjustment. Viewed in this way, CF PA+ sera had significantly lower opsonic activity than CF PA-sera (P < 0.025) or NHS (P < 0.0025), suggesting a qualitative opsonic defect in CF PA+ LPS IgG antibodies.
CF PA+ patients had highly elevated levels of alginate-specific IgG antibodies when compared with CF PA-patients or NHS (P < 0.005), who had similar levels of these antibodies (Table II) . Among CF patients, there was a positive correlation between levels of LPS and alginate IgG antibodies (r, = 0.65, P < 0.001). CF PA+ patients also had elevated levels of alginate-specific IgG2 subclass antibodies compared to CF PA-or NHS (P < 0.05). In contrast to antibody responses to LPS, IgG4 antibodies to alginate were detectable in only a few CF PA+ sera at low levels, suggesting lesser immunogenicity and possibly greater isotypic restriction to this antigen. There was a strong correlation between IgG and IgG2 antibody responses to alginate in CF patients (r, = 0.78, P < 0.000 1).
To determine whether LPS or alginate antibodies were more closely associated with opsonization, correlation coefficients were determined comparing IgG antibody levels in CF sera to peak PMN CL responses induced by opsonization of MPA with heat-inactivated sera. A correlation was found between IgG LPS antibody levels and CL responses (r, = 0.44, P = 0.01) but not for alginate (r, = 0.07), suggesting that opsonization of MPA may be mediated by LPS antibodies in CF sera. This would be consistent with PMN CL induction by LPS-producing MPA opsonized with Ps-ivIG and LPS-1 MAbs (Figs. 2 and 4) .
PA antibody specificities and opsonic responses in uncolonized CF patients. CF PA-serum samples were found to display a heterogeneity of opsonic activity in PMN CL assay, which fell into two quite different patterns shown in Fig. 6 . 5 of 14 CF PA-sera promoted a highly opsonic PMN CL response similar to that seen with CF PA+ sera, despite low ELISA levels, comparable to NHS, of LPS and alginate antibodies. This opsonization was not due to complement because it was not reduced by heat inactivation (Fig. 6 A) . However, most CF PA-sera induced PMN CL responses similar to those induced by NHS (Fig. 6 B) . Thus, 36% of CF PA-sera differed from NHS in the apparent presence of heat-stable factors that opsonized MPA without complement. Adjustment of CL responses for autologous alginate antibody levels did not suggest qualitative differences between CF PA+ and NHS as found with LPS antibodies. Nonopsonic antibodies in CF sera. The results seen in PMN CL assays after correcting for autologous IgG antibody levels ( Fig. 5) indirectly suggested that some LPS antibodies might be nonopsonizing in CF PA+ patients. Therefore, sera from 10 CF PA+ and 9 CF PA-patients were subjected to immunoadsorption with PA LPS and alginate. The adsorbed samples were then tested alongside native sera in PMN CL assay. As shown in Fig. 7 , removal of PA LPS antibodies from CF PA+ sera enhanced PMN CL responses in 4 of 10 patient samples and had no effect in two others. In contrast, adsorption of LPS antibodies from CF PA-sera uniformly inhibited PMN CL responses (mean net change, 51% inhibition; difference in group means significant at P < 0.01, Mann Whitney U test). Adsorption of alginate antibodies slightly decreased PMN CL mean responses in both groups (net change 27 vs. 7% inhibition in CF PA+ and CF PA-, respectively, ns). Interestingly, three CF PA-sera showed alginate blocking activity with 33-120% increase in PMN CL after alginate adsorption. Opsonicfunction ofisolated PA-I LPS IgG serum antibodies. To further assess the specificity and isotypic basis of diminished opsonic function of LPS antibodies in CF PA+ sera, IgG antibodies to PA LPS were isolated from sera by sequential ammonium sulfate precipitation, ion exchange chromatography, and immunoaffinity chromatography. BSA was used as a control for nonspecific adsorption of antibodies to activated Sepharose; separate aliquots ofeach processed serum sample were affinity purified on PA LPS and BSA, respectively.
PA LPS antibodies were isolated from sera of 11 CF PA+ sera and compared to those isolated from 12 CF PA-sera, pooled NHS, and Ps-ivIG. PA LPS antibody ELISA levels were determined on IgG fractions isolated from sera before and after LPS antibody affinity purification. The specificity of the purification was confirmed by high antibody levels from CF PA+ and Ps-ivIG fractions eluted off the LPS affinity column 0.09±0.03 for BSA eluate, P < 0.001). ELISA antibody levels in the isolates from the CF PA+ group were as expected severalfold higher than those in the CF PA-group (195±56 vs. 42±26 ELISA units, P < 0.025); Ps-ivIG level was 106 EU (not significantly different from CF PA+, one-saimple t test) and PNHS level was 7 EU (not significantly different from CF PA-). Isolated PA LPS IgG antibodies were adjusted to identical ELISA antigen-binding concentrations before opsonizing NMPA with complement in PMN CL assay. As shown in Fig.  8 , peak 90-min PMN CL induction was equivalent for PA LPS IgG antibodies isolated from Ps-ivIG (mean of seven separate opsonizations = 11.21±0.94 mV-s, 95% CI = 8.9-13.5), pooled NHS (mean of four opsonizations = 13.37±1.3, 95% CI = 9.1-17.6), and CF PA-(9.96±1.01, 95% CI = 7.7-12.2). Ps-ivIG, pooled NHS, and CF PA-serum derived antibodies all showed positive opsonic effect compared to PMN CL responses to unopsonized NMPA (P < 0.01-0.001).
In contrast, PMN CL induction by the isolated PA LPS IgG antibodies from CF PA+ sera (6.57±0.98, 95% CI = 4.4-8.8) was significantly lower than those from CF PA-(P < 0.05, two-tailed t test), Ps-ivIG (P < 0.01), or pooled NHS (P < 0.01). Dilution of antibody concentrations present in native samples to achieve equal antigen-binding concentrations for opsonization could not account for the reduced opsonization seen with CF PA+ sera because dilution of Ps-ivIG was as great as any CF PA+ serum sample, and several of the latter were diluted to a lesser extent but nevertheless had reduced activity. increases of 224±19, 267±27, and 199±20%, respectively, compared to 131±20% by the CF PA+ antibodies (P < 0.01-0.05).
Discussion
The salient features of the CF opsonic defect include the following four characteristics: antigenic restriction to PA (4-6); involvement of PA LPS IgG antibodies (7, 8) ; a more pronounced or easily detected inhibitory effect on lung macrophages compared to blood monocytes or neutrophils (9) ; and inducibility after stimulation with PA LPS (14) . To further characterize this phenomenon, we compared the opsonic activity of antibodies in CF PA+, CF PA-, and normal sera for nonmucoid and mucoid PA expressing LPS immunotype I antigens. All CF PA+ patients showed evidence of intense stimulation with PA LPS as reflected in high serum IgG antibody levels.
In addition, we considered the immune response to alginate, which is antigenically related to the exopolysaccharide slime produced in large quantities by mucoid morphotypes of PA (26) (27) (28) . Recently, Pier et al. suggested that uncharacterized subsets of mucoid exopolysaccharide antibodies may be protective against PA colonization in certain CF patients. A majority of older CF patients (2 12 yr) without PA colonization had elevated serum opsonic titers of antibodies capable of killing mucoid PA in conjunction with PMN and complement. These antibodies seemed specific for exopolysaccharide rather than LPS. Curiously, these sera did not show elevated titers ofexopolysaccharide-binding antibodies in an hemagglutination assay (30) . Our studies of the opsonization of MPA provide some support to these data, in that relatively high complement-independent PMN CL responses were induced by 36% of CF PA-sera tested despite low ELISA levels of LPS and alginate IgG antibodies. However, most of the CF PAsera in our sample population (ages 14-30 yr) showed opsonizing properties for MPA no different than those in normal control sera. It therefore seems unlikely that opsonizing antibodies for mucoid exopolysaccharide undetectable by antigen-binding immunoassays are major factors responsible for the absence of PA colonization in occasional older CF patients.
PMN play an essential role in normal systemic host defense against PA (31) . Before PMN can perform their bactericidal function they must first be activated to efficiently phagocytose the microbes and undergo an oxidative respiratory burst, a process usually dependent upon the presence of antibody and/or complement opsonins. However, great heterogeneity in opsonic requirements for different strains and phenotypes of PA has been documented. Most nonmucoid or mucoid strains of PA are opsonized primarily by complement in nonimmune serum (with an additional requirement for natural antibody by some strains), whereas antibody alone is sufficient in immune serum (31) (32) (33) (34) . PA strains dependent only upon antibody for opsonization, and strains phagocytosed efficiently by PMN in the absence of any soluble opsonins, have also been described (35) (36) (37) . Opsonization of our test NMPA strain was primarily antibody dependent, since PMN chemiluminescence responses were not significantly diminished after inactivation of complement. Chemiluminescence responses to this strain are similar to those Allen and Lieberman found in NMPA strains using complement-depleted rabbit immune serum opsonins (38) . In contrast, the CF-derived MPA test strain was dependent upon complement for optimal opsonization by nonimmune serum, as has been reported for other MPA strains (33, 39).
Immunotype-specific IgG antibodies are directed against carbohydrate epitopes on PA LPS side chains and are potent opsonins (40). Insufficient or abnormal serum PA LPS IgG antibodies predispose to PA infections and adversely affect prognosis (41) . CF patients are initially colonized with typical smooth LPS side chain-producing PA strains (42). Over time, the unique CF endobronchial environment induces or allows a number of changes in the phenotype of the colonizing PA strains, including emergence of the characteristic mucoid morphotype (due to increased exopolysaccharide production), and decreased LPS side chain production (24) . Despite this phenotypic evolution, serotype-specific IgG antibodies to PA LPS persist at high titer throughout the course of the disease (19, 43, 44) . Recent studies confirm persistent low-level production of LPS side chains by many CF-derived PA strains (44, 45 ).
Fick and co-workers reported that PA LPS IgG antibodies isolated from serum of CF PA+ patients opsonized NMPA for phagocytosis by human lung macrophages less efficiently than comparable antibodies isolated from normal immune donors. A defective interaction between the Fc antibody region and lung macrophage Fcy receptors was implicated (7). Subsequently, they found that similar antibodies from CF bronchoalveolar lavage fluid were also defective, but in this case a localized proteolytic degradation of immunoglobulin was suggested as a major mechanism (8) . However, proteolysis, while potentially contributing to opsonic dysfunction, does not adequately account for the specificity of defective CF opsonins. We therefore undertook studies to further characterize the nature of the defect.
For our opsonic studies we used blood PMN rather than lung macrophages as an easily accessible and convenient target cell to further analyze antibody-phagocyte interactions, knowing that differences between CF PA+ and CF PA-or normal serum opsonins might be more difficult to demonstrate. For example, Thomassen et al. found CF PA+ sera-induced phagocytic inhibition more pronounced with macrophages than monocytes or PMN (9) . On the other hand, Holland et al. reported depressed PMN phagocytosis of rabbit antihuman immunoglobulin-coated polyacrylamide beads in the presence of CF PA+ sera (46) . Since this inhibition was probably not due to immune complexes, it is possible that it represented binding of poorly opsonic CF PA+ antibodies by the rabbit antihuman immunoglobulin with subsequent depression of Fc-yR-mediated uptake by PMN. Second, we employed serum rather than bronchoalveolar lavage (BAL) CF opsonins, for several reasons: they are easily accessible; they are standardized in terms of other constituent proteins, in contrast to BAL where dilutional and processing artifacts are likely; and, again in contrast to BAL, they are not demonstrably fragmented. Therefore, opsonic differences between CF PA+ serum antibodies and their counterparts in CF PA-or NHS must have another basis.
Among our patients the opsonic activity of native decomplemented CF PA+ sera for nonmucoid or mucoid PA was greater than that in normal or CF PA-sera, and roughly equivalent to that of hyperimmune globulin prepared from normal blood donors. The increased PMN chemiluminescence-inducing activity ofCF PA+ sera is consistent with local containment of PA and the virtual absence of PA sepsis in CF. It also represents a potential mechanism of airways inflammation via extracellular release of reactive oxygen intermediates from local PMN (47) . LeBlanc and co-workers also found increased PMN chemiluminescence induced by PA opsonized with CF PA+ sera (48) . Recently, Bender et al. reported increased PMN superoxide anion production induced by CF PA+ sera (47) .
These prior studies did not examine antibody specificities or content in the sera. After adjustment ofchemiluminescence values for autologous PA LPS IgG antibody levels, we found that CF PA+ sera had diminished equititer opsonic activity when compared to CF PA-and normal nonimmune sera. This analysis suggested that qualitative defects in CF PA+ LPS antibodies might be present but compensated for by the pronounced, broad, and polyisotypic antibody responses that follow PA colonization.
Evidence for this hypothesis came from two sets of experiments. First, after immunoprecipitation of PA LPS antibodies from CF PA+ sera opsonic activity was enhanced in 4 of 10 sera and unaffected in two others, while that of CF PA-sera was uniformly inhibited. In contrast, there was no compelling evidence that alginate antibodies were potent opsonins; in fact, alginate-specific blocking activity appeared present in three of nine CF PA-sera tested. Second, after PA LPS IgG antibodies were isolated and purified from serum by immunoaffinity chromatography, induction of PMN CL by CF PA+ antibodies was significantly lower than that from noncolonized CF patients, normal nonimmune controls, or immune controls at equal antigen-binding antibody concentrations (Fig. 8) (30, 49, 50) . Further studies are needed to define potential mechanisms underlying differences in opsonic function of antibodies directed against various PA antigens, such as isotype restriction determined by antigen composition and/or structure (e.g., protein versus carbohydrate).
A candidate mechanism for induction of nonopsonic antibodies is antigen-induced alteration of IgG antibody isotype (12, 13) . To study the relationship between antibody isotype and opsonic function, we employed a set of isotype switch variant PA LPS specific murine monoclonal antibody clones of IgG2a, IgG2b, and IgM classes. In these experiments clear isotype-based differences in opsonic activity were demonstrated (Figs. 3 and 4) . Furthermore, in preliminary studies we have found evidence that polyclonal PA LPS antibodies of different IgG subclasses isolated from human serum also show opsonic differences in vitro (manuscript in preparation) (5 1).
An answer to the second critical question, what role nonopsonic LPS antibodies could play in PA persistence when other opsonic antibodies compensate for their presence in PMN phagocytic studies, is not possible with the data available. In the first place, the experiments reported here do not address the potential in vivo role of pathogen-related factors such as microcolony formation or exoproteins, or the role of nonimmune host factors such as altered respiratory secretions or complement-related opsonic defects, which may be important in PA persistence. It seems more likely than not that PA persistence results from several interacting host-and pathogen-based phenomena. Secondly, our methodology also imposed inherent limitations. For example, there is likely to be a greater impact of nonopsonic LPS antibodies upon lung macrophage than PMN phagocytic activity, potentially amplifying the local effect (3, 4, 9) . It is also possible that in the airways microenvironment adjacent to colonizing PA, opsonic antibodies may ineffectively compete with high local concentrations of nonopsonic LPS antibodies. If so, nonopsonic antibodies could play a role in the pathological shift in inflammatory cell predominance from macrophage to PMN seen in the CF lungs, a shift believed crucial in the evolution of progressive lung injury (52) . Ineffective phagocytosis by macrophages with PA persistence could drive recruitment, activation, and degranulation of PMN with associated progression of lung disease. In later stages of the disease process, nonopsonic LPS antibodies could dampen PMN-related inflammation, contributing to the indolence and chronicity of CF lung disease.
Clearly, further investigation focusing on local in situ conditions at various stages of the disease is required to resolve current ambiguities. However, the development of nonopsonic LPS antibodies shows that the potential for a maladaptive host immune response to PA is realized in at least one antigen-specific instance, and may therefore indicate that other analogous responses also exist. In addition, this phenomenon may help explain the paradox of PA persistence and local lung inflammation existing side-by-side with decades-long chronicity, containment of infection, and intact systemic immunity to PA in cystic fibrosis.
